Wednesday, October 27, 2021

Grand Rounds

11:00 AM to 12:00 PM
CME credit available, click here
Attendance must be registered within 6 months to be awarded credit.
Recorded archives of live activities are considered enduring materials. Viewing of a recorded session is for reference only, no CME credit can be claimed.

Virtual Event

Zoom ID: 983 3802 4406 Passcode: NeuroGR

"From Rare to Common: Measuring Progression in Neuropathy"

Dr. Vera Fridman

Associate Director, Medical Student Education

Vera Fridman, MD is an Associate Professor in the Neuromuscular Section at the University of Colorado’s (CU) Anschutz Medical Campus, clinical director of the Charcot-Marie-Tooth Association Center of Excellence at the University of Colorado Hospital, and Associate Director of Medical Student Education for the Department of Neurology. She earned her BS in Neuroscience at Brandeis University and MD at Tufts University before completing Neurology Residency at the University of Pennsylvania where she was awarded the Penn Pearls Award for Excellence in Clinical Teaching and Steven L. Galetta Resident Teaching Award. Dr. Fridman then completed a Neuromuscular Disease Fellowship at Brigham and Women’s and Massachusetts General Hospitals, followed by a Clinical Research Fellowship in Hereditary Neuropathy at Queen Square, University of Iowa, and University of Rochester Hospitals and Clinics. Dr. Fridman then joined the faculty at Harvard Medical School and Massachusetts General Hospital where she carried out a biomarker, natural history study, and 2-year trial in Hereditary Sensory Autonomic Neuropathy Type 1 (HSAN1) which demonstrated clinical improvement of neuropathy in response to treatment with L-serine, one of the first biologically rational therapies for a hereditary nerve disease.


Dr. Fridman’s research to date has focused on paving the way for, and executing, treatment trials for neuropathy. She completed a longitudinal natural history study of inherited neuropathy in the largest patient cohort reported to date in partnership with the Inherited Neuropathy Consortium Rare Disease Clinical Research Network and investigated the role of atypical, neurotoxic sphingolipids in diabetic neuropathy as a member of the Colorado Clinical and Translational Science Institute’s Clinical Faculty Scholars Program. She is currently further evaluating the role of atypical, deoxysphingolipids in diabetic neuropathy in patients with type 2 diabetes through an NIH Mentored K23 Patient-Oriented Research Career Development Award supported by the National Institute of Diabetes and Digestive and Kidney Diseases.